Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Genes May Predict Response to Sole Sickle Cell Drug

Published: Friday, February 22, 2013
Last Updated: Friday, February 22, 2013
Bookmark and Share
Only one drug is currently available under FDA regulations, but response varies greatly from patient to patient.

Hydoxyurea is an almost ideal drug for many children with sickle cell anemia. It reduces the severe pain and long-term organ damage caused by sickled blood cells; it can improve lifespan; and it is cheap and fairly safe. And it’s the only FDA-approved medication for sickle cell anemia.

What’s not ideal is the variable response to the drug. “Right now, you just don’t know what’s going to happen when you start a patient on hydroxyurea,” said Nancy Green, MD, associate professor of pediatrics. “Some have only a modest response, while for others, the drug changes the disease, keeps them out of the hospital, and gets them back to their lives.”

“If the drug isn’t going to do much for a patient, we want to know so we can start thinking about other options, blood transfusions or a bone marrow transplant, that are not as easy or readily available.”

Genetic differences among patients undoubtedly play a role. With the help of a consortium she organized—with researchers from Albert Einstein, Weill-Cornell, Yale, Oakland Children’s, and the University of Rochester—Green is now starting to identify genes that eventually may help physicians better predict response to hydroxyurea.

In sickle cell disease, a mutation in the hemoglobin gene causes the hemoglobin molecules inside red blood cells to stick to each other. When that happens, the cells become damaged and lose their flexibility, causing them to assume a sickle shape. If patients also produce enough fetal hemoglobin—normally produced only in very small amounts after birth—more red blood cells retain their normal round shape and flow through the microvasculature throughout the body. Hydroxyurea works in large part because it increases the production of fetal hemoglobin, thereby reducing sickling and its complications.

The amount of fetal hemoglobin patients can produce on their own is often an indication of the degree to which they will respond to the drug, but not always. Many patients with high baseline levels fail to mount a large fetal hemoglobin response to the drug, while fetal hemoglobin sometimes surges even in patients with low baseline levels.

A recent study published by Green and her colleagues in PloS One looked at predictors of hydroxyurea response in 117 children and found that baseline levels of fetal hemoglobin explain 33 percent of the variation in patient response.

That percentage increased to almost 50 percent when the researchers factored in each patient’s type of epsilon globin gene. Green and her team also found other genes that seem to be linked to the fetal hemoglobin response to drug, but those will need to be investigated in future studies with more patients.

“Our genetic results still need to be confirmed by other researchers, and we need to find the factors that control the other 50 percent of the variation in response, but I think we will soon get to a point when we can more reliably predict who will do well on hydroxyurea,” Green said.

“With a prediction tool, we could identify patients who should benefit but aren’t because of difficulty adhering to the daily regimen. And we could offer the drug earlier to those who are most likely to respond,” she said.

“For many children with sickle cell disease, the earlier they start using hydroxyurea, the greater impact it will have on their lives.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Thursday, November 26, 2015
What Do Animal Viruses Have to Do with Human Health?
Simon Anthony studies animal infections to prevent outbreaks in people.
Monday, September 28, 2015
Dentists Tapped for New Role: Drug Screenings
A visit to the dentist has the potential to be more than a checkup of our teeth as patients are increasingly screened for medical conditions like heart disease and diabetes.
Tuesday, August 18, 2015
Computer Model Forecasts Flu Outbreaks in Subtropical Climate
Study in Hong Kong predicts outbreaks by flu strains and is first to forecast flu in a subtropical climate.
Friday, August 07, 2015
Long-term Memories Are Maintained by Prion-like Proteins
Research from Eric Kandel’s lab at Columbia University Medical Center has uncovered evidence of a system in the brain that persistently maintains memories for long periods of time.
Friday, July 03, 2015
Scientists are Designing Decoy Drugs to Fool Cancer
Study shows potential of drugs that can target the Notch switch with reduced toxicity.
Thursday, May 28, 2015
DNA Abnormalities Found in Children with Chronic Kidney Disease
Routine genetic screening of children with CKD could lead to earlier, more precise diagnoses.
Tuesday, April 21, 2015
Patient-Specific Stem Cells and Personalized Gene Therapy
Patients’ own cells transformed into model for studying disease and developing potential treatment.
Saturday, July 12, 2014
Chips that Listen to Bacteria
Researchers have developed a chip that enables them to electrochemically image the signaling molecules from colonies spatially and temporally.
Thursday, February 27, 2014
Study Shows Where Alzheimer’s Starts and How It Spreads
The findings could improve early detection of the disease, when drugs may be most effective.
Tuesday, December 24, 2013
Global Study Discovers Flurry of New Alzheimer’s Genes
An international study has uncovered 11 new genes that increase the chance of developing Alzheimer’s disease and provide new clues to ways of fighting it.
Wednesday, October 30, 2013
Test Could Identify Which Prostate Cancers Require Treatment
3-gene biomarker gauges tumor’s aggressiveness.
Thursday, September 12, 2013
Columbia Licenses Novel 3-D Organ and Tumor Segmentation Software to Varian Medical Systems
Allows for more precise and efficient planning and monitoring of cancer treatment.
Friday, May 17, 2013
High Level of Antibodies Linked to Cognitive Decline
Researchers found that people with high levels of antibodies to five common infections in their blood, previously shown to be associated with increased risk of cardiovascular disease, also are associated with an increased risk of cognitive decline.
Thursday, March 28, 2013
Improper Protein Digestion in Neurons Identified as a Cause of Familial Parkinson’s
Researchers at CUMC and others have discovered how the most common genetic mutations in familial Parkinson’s disease damage brain cells.
Friday, March 08, 2013
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
The MaxSignal Colistin ELISA Test Kit from Bioo Scientific
Kit can help prevent the antibiotic apocalypse by keeping last resort drugs out of the food supply.
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Closing the Loop on an HIV Escape Mechanism
Research team finds that protein motions regulate virus infectivity.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos